Opyl : 2021 Annual Report to shareholders

For personal use only

Annual Report 2021

Contents

For personal use only

Highlights

The Opyl story - what, why and how

Chairman and CEO's letter to shareholders

A year in review

Opyl leadership

Opyl business structure

Opyl people

Director's Report

Declaration of independence

Statement of profit or loss and other income

Director's declaration

Shareholder information

Corporate directory

Opyl Ltd Engine House

105 Wellington Street

St Kilda Victoria 3182, Australia [e-mail]

www.opyl.ai

www.opin.ai

ABN 71 063 144 865

ASX:OPL

5

6

8

10

14

18

19

20

34

36

59

64

68

Share Register: Automic Pty Ltd Level 5,126 Phillip Street Sydney NSW 2000, Australia [phone] (within Australia) [phone] (outside Australia) [e-mail]

2

For personal use only

Our purpose is to collect consented real-world health " data, to match eligible, motivated patients to clinical trials

• anywhere in the world, and employ an AI enabled systems approach to design smarter clinical research protocols with a higher probability of success - everybody wins

Michelle Gallaher. CEO, Opyl Ltd.

For personal use only

Our goals

Opyl's core goal is to realise value from completing development and achieving scalable commercialisation of its two clinical trial optimisation platforms Opin and Trialkey, and continue to expand our bespoke social media insights offering for the global biopharma, medtech and health industry.

Establish Opin as a market leader in the

$AUD$4.7bn [3] global clinical trial recruitment

• solutions market, with demonstrable expertise and 6% market share in the rapidly growing APAC market by 2024 year end [3]

Complete development and full commercialisation of Opyl's two clinical trial optimisation platforms

• (Opin and Trial Key) by 2024 year end, unlocking scalable service offering and new revenue streams

Transition the focus of all available and existing Opyl internal services resources and outbound business

• development effort into clinical trial recruitment, revenue growth and partnering to drive the expansion of Opin over coming 12 months

Attract and develop the best talent with expertise and passion to build and maintain a creative, ethical, diverse, ambitious, accountable, and

• collaborative culture, as well as deliver technical and commercial excellence focused on value and sustainability

Work within and contribute to an informed and

• ethical global digital health industry ecosystem

Ref: [3] Patient Recruitment and Retention Services Market 2nd Edition, 2021-2030. June 2021. Roots Analysis.

4

For personal use only

Highlights

Opin launched May 2021, on time and on budget

Opin establishes a new scalable clinical trial recruitment revenue stream

Revenue up 26% to $1.24m

Operating loss $1.12m cut by 22% year on year

Opyl team expanded by 18% adding BD, data analytics and SEO growth skills

Closing cash balance $2.32m

Trial Key successfully completes proof of concept data trial on COVID vaccine predictions

WFH implemented smoothly

AUD$2.68m SPP and private placement, before costs

Improved cash position

2 new board appointments, strengthening tech scaleup and clinical trials skills

Social Insights offering attracts new global biopharma and medtech clients, exceeding revenue expectations

3 scalable data-centric solutions for the global	Social Insights
health tech market developed in less that three
years, with two generating early revenue
Unmarketable parcel buy back of 373k shares

5